A new physiologically based pharmacokinetic model for the prediction of gastrointestinal drug absorption: Translocation model

Drug Metabolism and Disposition

Volumn 43, Issue 4, 2015, Pages 590-602

  Ando, Hirotaka ^a,b   Hisaka, Akihiro ^a,c   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; MIDAZOLAM; DRUG;

ACCURACY; ANATOMICAL VARIATION; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BLOOD FLOW; CACO 2 CELL LINE; CELL EXPANSION; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; LAMINA PROPRIA; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSLOCATION MODEL; BIOLOGICAL MODEL; COMPUTER SIMULATION; GASTRIC MUCOSA; INTESTINE CELL; INTESTINE MUCOSA; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY; PREDICTIVE VALUE; TISSUE DISTRIBUTION;

CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; ENTEROCYTES; GASTRIC MUCOSA; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; TISSUE DISTRIBUTION;

EID: 84940045984     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.060038     Document Type: Article

References (51)

1. Agoram B, Woltosz WS, and Bolger MB (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50(Suppl 1):S41-S67.
2. Badhan R, Penny J, Galetin A, and Houston JB (2009) Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 98:2180-2197.
3. Bergstrand M, Söderlind E, Eriksson UG, Weitschies W, and Karlsson MO (2012) A semimechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations. Pharm Res 29:695-706.
4. Bergstrand M, Söderlind E, Weitschies W, and Karlsson MO (2009) Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Clin Pharmacol Ther 86:77-83.
5. Bolger MB, Lukacova V, and Woltosz WS (2009) Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 11:353-363.
6. Bornemann LD, Min BH, Crews T, Rees MM, Blumenthal HP, Colburn WA, and Patel IH (1985) Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 29:91-95.
7. Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, and Panis Y, et al. (2010) Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 7:1596-1607.
8. Chen J and Pang KS (1997) Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. J Pharmacol Exp Ther 280:24-31.
9. Cong D, Doherty M, and Pang KS (2000) A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28:224-235.
10. Cong D, Fong AK, Lee R, and Pang KS (2001) Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. Drug Metab Dispos 29:1539-1547.
11. De Sesso JM and Jacobson CF (2001) Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209-228.
12. Ekins S, Bravi G, Wikel JH, and Wrighton SA (1999) Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 291:424-433.
13. Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, and Artursson P (2006) Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277.
14. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
15. Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633-1642.
16. Heikkinen AT, Baneyx G, Caruso A, and Parrott N (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci 47:375-386.
17. Hénin E, Bergstrand M, Standing JF, and Karlsson MO (2012) A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model. AAPS J 14:155-163.
18. Hisaka A, Nakamura M, Tsukihashi A, Koh S, and Suzuki H (2014) Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions. Drug Metab Dispos 42:1640-1645.
19. Hisaka A, Ohno Y, Yamamoto T, and Suzuki H (2010) Theoretical considerations on quantitative prediction of drug-drug interactions. Drug Metab Pharmacokinet 25:48-61.
20. Hisaka A and Sugiyama Y (1998) Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J Pharmacokinet Biopharm 26:495-519.
21. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, and Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225-237.
22. Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256.
23. Kalampokis A, Argyrakis P, and Macheras P (1999) Heterogeneous tube model for the study of small intestinal transit flow. Pharm Res 16:87-91.
24. Kimura T and Higaki K (2002) Gastrointestinal transit and drug absorption. Biol Pharm Bull 25:149-164.
25. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, and Liu KH (2008) The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 36:986-990.
26. Lavrijsen KL, Van Houdt JM, Van Dyck DM, Hendrickx JJ, Woestenborghs RJ, Lauwers W, Meuldermans WE, and Heykants JJ (1988) Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes. Anesthesiology 69:535-540.
27. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
28. Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, and Sugiyama Y (2011) Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther 90:263-270.
29. Misaka S, Uchida S, Imai H, Inui N, Nishio S, Ohashi K, Watanabe H, and Yamada S (2010) Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. Clin Exp Pharmacol Physiol 37:290-295.
30. Ohura K, Nozawa T, Murakami K, and Imai T (2011) Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. J Pharm Sci 100:3985-3994.
31. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
32. Pang KS and Chow EC (2012) Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model. Drug Metab Dispos 40:1869-1877.
33. Parker KL, Brunton LL, and Lazo JS, editors (2005) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed, McGraw-Hill Companies, Inc., New York.
34. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, and Knutson L, et al. (2003) Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 31:805-813.
35. Polasek TM, Sadagopal JS, Elliot DJ, and Miners JO (2010) In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol 66:275-283.
36. Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, and He H, et al. (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 100:4127-4157.
37. Rotzinger S, Fang J, and Baker GB (1998) Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 26:572-575.
38. Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Mönnikes H, Hosten N, and Weitschies W (2005) Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22:971-979.
39. Schulz R and Winne D (1987) Relationship between antipyrine absorption and blood flow rate in rat jejunum, ileum, and colon. Naunyn Schmiedebergs Arch Pharmacol 335:97-102.
40. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, and Warhurst G (2001) Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-591.
41. Sugano K (2009) Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol 5:259-293.
42. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, and Amidon GL (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12, 000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19:1400-1416.
43. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, and Sugiyama Y (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27:442-446.
44. Tam D, Tirona RG, and Pang KS (2003) Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31:373-383.
45. Thomas S, Brightman F, Gill H, Lee S, and Pufong B (2008) Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci 97:4557-4574.
46. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, and Troutman MD (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098-1108.
47. Willmann S, Schmitt W, Keldenich J, and Dressman JB (2003) A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 20:1766-1771.
48. Willmann S, Schmitt W, Keldenich J, Lippert J, and Dressman JB (2004) A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031.
49. Winne D (1978) Blood flow in intestinal absorption models. J Pharmacokinet Biopharm 6:55-78.
50. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
51. Yu LX and Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.